IPP Bureau
Botanical Solution Inc. raises $6.1 million in Series A
By IPP Bureau - January 27, 2022
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
Cipla’s Q3FY22 PAT at Rs 729 cr.
By IPP Bureau - January 26, 2022
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Mandaviya reviews public health preparedness to Covid-19
By IPP Bureau - January 26, 2022
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Roche’s Evrysdi granted USFDA priority review for treatment of spinal muscular atrophy
By IPP Bureau - January 26, 2022
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Torrent Pharmaceuticals consolidated PAT at Rs 249 cr
By IPP Bureau - January 26, 2022
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Quantori names Arun Nayar as Global Head of R&D Informatics
By IPP Bureau - January 26, 2022
New role strengthens Quantori’s global leadership position in data science & digital IT
Polycarbin breaks the single-use scientific plastic mold
By IPP Bureau - January 26, 2022
Closing the Loop on single-use plastics
Intellect closes US $10 m Series A to scale mental healthcare across Asia
By IPP Bureau - January 26, 2022
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.
By IPP Bureau - January 26, 2022
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
Philips introduces at-home, 12-lead ECG integrated solution for trials
By IPP Bureau - January 26, 2022
Philips expands remote cardiac monitoring portfolio with patch-based, clinical-grade ECG designed to improve patient recruitment, compliance and retention by reducing need for site visits during clinical trials
JBCPL to acquire brands from Sanzyme for Rs 628 cr
By IPP Bureau - January 26, 2022
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
JSW opens 300-bed covid centre in Karnataka
By IPP Bureau - January 25, 2022
The covid health center will be managed and administered by the district administration of Ballari
Agilent announces the Innovative Seahorse XF Pro Analyzer
By IPP Bureau - January 25, 2022
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
USFDA rejects Merck’s gefapixant; gain approval in Japan
By IPP Bureau - January 25, 2022
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Medtronic gets USFDA approval of spinal cord stimulation therapy
By IPP Bureau - January 25, 2022
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone